Why Roivant Sciences Stock Is Soaring Today

Key Points

• Roivant and Priovant Therapeutics announced positive results from a phase 3 study of brepocitinib.

• The drug could have blockbuster potential in treating rare and orphan autoimmune diseases.

• 10 stocks we like better than Roivant Sciences ›

Shares of Roivant Sciences (NASDAQ: ROIV) are soaring 11.4% higher as of 11:19 a.m. ET on Wednesday. The big gain came after Roivant and Priovant Therapeutics announced positive results from a late-stage clinical study evaluating brepocitinib in treating dermatomyositis, an autoimmune disease that can cause muscle weakness and skin lesions.

Patients receiving a once-daily 30 mg dose of oral brepocitinib experienced statistically significant improvement compared to placebo on the primary endpoint of the phase 3 clinical study as well as all nine key secondary endpoints. Brepocitinib's safety profile was also encouraging, with adverse events of special interest such as malignancy, cardiovascular events, and thromboembolic events not occurring at a greater frequency than with patients in the placebo arm of the study.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

What does this news mean for Roivant?

Priovant Therapeutics now plans to file for U.S. Food and Drug Administration (FDA) approval of brepocitinib in treating dermatomyositis in the first half of 2026. That's great news for Roivant for a simple reason: It owns 75% of Priovant.

Roivant believes that brepocitinib has the potential to become a blockbuster drug treating rare and orphan autoimmune diseases. Dermatomyositis affects around 50,000 adults in the U.S. There's only one approved therapy for the disease, and no other oral therapies are in late-stage development.

Image source: Getty Images.

Is Roivant stock a buy?

Roivant probably won't be appealing to risk-averse investors. However, the stock looks like a good pick for aggressive investors. In addition to brepocitinib, Roivant's pipeline features two other candidates in late-stage development, IMV-1402 and batoclimab. IMV-1402, in particular, holds the potential to be a big winner if approved.

Should you invest $1,000 in Roivant Sciences right now?

Before you buy stock in Roivant Sciences, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Roivant Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $647,425!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,071,739!*

Now, it’s worth noting Stock Advisor’s total average return is 1,056% — a market-crushing outperformance compared to 189% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of September 15, 2025

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy.